Job Description

Job Summary
We are looking for a dynamic PSR (Professional Sales Representative) to drive product sales and promotion within pharmacies and medical facilities within PTA East region for CNS therapy. Your role will be pivotal in implementing sales strategies, organizing promotional activities, and building strong client relationships to achieve company objectives and maximize market penetration.

Roles & Responsibilities

To report product complaints (adverse events & product technical complaints) and medical information queries for all DRL products as per internal processes.
You will be responsible for selling, detailing and promoting products to targeted pharmacies and dispensing doctors in a designated area.
You will be responsible for assisting, organizing and presenting commercial activities within Pharmacies as well as programmes and promotional events in the designated area and/or nationally.
You will be responsible for implementation of action plans in accordance with the marketing/sales strategy of the company.
You will be responsible for personally visiting and liaising with the relevant target clients crucial to the performance of the company as agreed with the respective KAM (Key Account Manager)/National Sales and KAM.
Your role extends to maintaining a data-base of all targeted clients and liaising with the KAM/National Sales to effectively leverage various business opportunities in the designated areas.

Qualifications

Educational qualification: Diploma or Bachelor’s Degree in Lifesciences, Marketing or sales
Minimum work experience: 3-5 years of Pharma Industry Experience

Skills & attributes:

Thorough understanding of the SA (South Africa) Pharmaceutical Industry and knowledge of health care related events.
Ability to solidify and expand business relationships.
Ability to convey messages and motivate certain audiences.
Ability to efficiently manage budget and resources within the scope of the business model and expense policy guidelines.
Demonstrated ability to sell products and achieve sales targets.
Demonstrated ability to learn product/disease entity information.
Ability to work independently as well as collaboratively in a fast-paced, high energy organization.
Understanding of pharmaceutical marketing principles.
Excellent verbal and interpersonal skills.
Computer literacy.
High level of integrity and adherence to all compliance guidelines.
Customer-focused and performance-driven.
Entrepreneurial, innovative, egalitarian, and trusting.
Flexible and adaptive.

Additional Information

About the Department
Global Generics India
Global Generics India business journey began in 1986. In the last three decades, we have grown as a trusted name in the healthcare industry and rank as one of the top 10 Pharma Companies in the Indian Pharma Market (IPM) as per IQVIA MAT (November 2022). Our commitment to Lead Ahead has helped us move ranks from 16th position to 10th position (IPM) in the last four years. We are a fast-growing organisation with double-digit growth and significant market share in domestic markets. Currently, we rank among the top 5 in oncology, anti-allergy and gastrointestinal diseases and the top 10 in a few other therapy areas. Our focus is on leveraging our digital capabilities, collaborations, innovations and inorganic opportunities to become the top 5 companies in the Indian Pharma Market.

Benefits Offered
At Dr. Reddy’s we actively help to catalyse your career growth and professional development through personalised learning programs.
The benefits you will enjoy at Dr. Reddy’s are on par with the best industry standards. They include, among other things and other essential equipment, joining & relocation support, family support (Maternity & Paternity benefits), learning and development opportunities, medical coverage for yourself and your family, life coverage for yourself.

Our Work Culture
Ask any employee at Dr. Reddy’s why they come to work every day and they’ll say, because Good Health Can’t Wait. This is our credo as well as the guiding principle behind all our actions. We see healthcare solutions not only as scientific formulations, but as a means to help patients lead healthier lives, and we’re always attuned to the new and the next to empower people to stay fit. And to do this, we foster a culture of empathy and dynamism. People are at the core of our journey over the last few decades. They have been supported by an enabling environment that buoys individual ability while fostering teamwork and shared success. We believe that when people with diverse skills are bound together by a common purpose and value system, they can make magic.
For more details, please visit our career website at https://careers.drreddys.com/#!/

About the company

Dr. Reddy's Laboratories focuses on affordable generic medicines and pharmaceutical ingredients. Its products include generic drugs and active pharmaceutical ingredients (APIs) produced in-house and distributed worldwide. The company grew from a Hyderabad-based startup in 1984, becoming the first Indian firm to export APIs to Europe in 1986 and to enter the U.S. market in the early 1990s, culminating in a 2001 NYSE listing that underscored its global standards. Today, the group operates in over 150 countries, supported by ongoing research and development to create new and improved medications. The core goal is to improve global health by providing high-quality, affordable healthcare solutions at scale.

Company Size

10,001+

Company Stage

IPO

Headquarters

Hyderabad, India

Founded

1984

Get referred to Dr. Reddy's Laboratories

See people who can refer or advise you

Simplify's Take

What believers are saying

Obeda semaglutide launched in India on March 21, 2026 after the Novo cliff.
Q1 FY27 revenue reached INR 8,071 crores on July 22, 2026, with 7.4% sequential growth.
North America sales rebounded 19% sequentially, and net cash stayed INR 3,057 crores.

What critics are saying

July 22, 2026 semaglutide batch provisions cut EBITDA and triggered investor investigations.
North America revenue fell 41% year over year in Q1 FY27, exposing U.S. concentration.
Any FDA finding at the semaglutide plant would freeze launches and crush margins for quarters.

What makes Dr. Reddy's Laboratories unique

Dr. Reddy’s first-to-market Bosutinib launch on June 13, 2026 earned 180-day exclusivity.
Canada approved generic semaglutide first, giving Dr. Reddy’s G7 mover advantage on April 28, 2026.
Hyderabad-based MSN partnerships and global supply chains support complex injectables and oncology launches.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Life Insurance
Parental Leave
Relocation Assistance
Professional Development Budget

Growth & Insights and Company News

6 month growth

12%

1 year growth

12%

2 year growth

12%

Yahoo Finance

Oct 25th, 2026

Dr Reddy's Q2 revenue falls 1.5% to $905M as margin recovers to 20.6%

Dr Reddy's Laboratories reported second-quarter revenue of INR8,671 crore ($905 million), down 1.5% year on year but up 7.4% from the previous quarter. Lower sales of lenalidomide drove the decline. Profit after tax was INR925 crore ($97 million). EBITDA margin was 20.6%, and gross margin rose to 52.1%. The company targets a gross margin of about 55%. North America generics revenue fell 29% year on year to $264 million. India grew 17% and emerging markets 84%. Dr Reddy's expects to resume semaglutide supply in November 2026. The US Food and Drug Administration's decision date for its abatacept biosimilar is December 22, 2026.

Yahoo Finance

Oct 23rd, 2026

Dr. Reddy's Q2 revenue falls 1.5% to $905M as semaglutide relaunch set for November

Dr. Reddy's Laboratories reported second-quarter FY2027 revenue of INR 8,671 crore ($905 million), down 1.5% year over year but up 7.4% from the previous quarter. Lower North American lenalidomide sales drove the fall, while the underlying business grew at a double-digit rate. EBITDA was INR 1,783 crore ($186 million), a 20.6% margin. Management expects margins to stay above 20% and targets 25% over the longer term. The company expects to relaunch semaglutide in November 2026, subject to validation of its revised API. It kept its target of 6 million to 7 million devices for the fiscal year, with most initial supply going to Canada. Profit attributable to equity holders was INR 925 crore ($97 million).

The Hindu BusinessLine

Oct 8th, 2026

FSSAI issues notice to Dr. Reddy's, Nestle Health Science, e-comm players over misleading claims.

FSSAI issues notice to Dr. Reddy's, Nestle Health Science, e-comm players over misleading claims. The notice was issued regarding non-compliant advertising and claims for "Celevida GLP+" on e-commerce platforms. Updated - October 08, 2026 at 09:46 PM. New Delhi, October 8 The Food Safety and Standards Authority of India (FSSAI) on Thursday said it has issued notices to Dr. Reddy's and Nestle Health Science Ltd besides Flipkart India, Amazon India, Netmeds Healthcare and Tirupati Wellness Pvt Ltd over alleged non-compliant claims and ads regarding a nutritional supplement. The regulator said the notice was issued regarding "non-compliant advertising and claims for "Celevida GLP+" on e-commerce platforms." In a social media post, the regulator said the product was found to be advertised as "High protein support for lean muscle preservation during GLP1/GLP therapies". "Such claims were found to imply suitability for a specific physiological condition. The brand name "Celevida GLP+", along with the GLP-1/GIP therapy-related claims, was found to create a misleading association between the product and such therapies," FSSAI added. It added that claims of "Help Maintain Lean Muscle", "support muscle strength" and "preserves lean mass" were found "to imply that the product may help mitigate loss of lean body mass during weight loss and GLP-1/GIP therapy." THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.

Exy Intellectual Property Sdn Bhd

Aug 24th, 2026

The March 20, 2026 Semaglutide patent cliff: strategic analysis of India's GLP-1 market realignment.

The March 20, 2026 Semaglutide patent cliff: strategic analysis of India's GLP-1 market realignment. The landscape of metabolic healthcare and chronic disease management across global markets experienced a historic shift on March 20, 2026. With the official expiration of Novo Nordisk's key formulation patent in India (IN 262697), market exclusivity for Semaglutide - the active pharmaceutical ingredient behind Ozempic and Wegovy - came to an end. Following favorable interim rulings from the Delhi High Court, top domestic pharmaceutical leaders immediately launched affordable generic GLP-1 alternatives on March 21. The legal & judicial foundations: freedom-to-operate in India. The post-patent rollout of generic Semaglutide was catalyzed by several landmark judicial and regulatory determinations: * Dismissal of Patent Extension Claims: Indian courts reaffirmed strict statutory thresholds against secondary "evergreening" attempts under Section 3(d) of the Patents Act, ensuring that basic formulation tweaks could not indefinitely extend market exclusivity beyond the March 20, 2026 barrier. * Pre-Expiry Export Clearance (The Delhi High Court Ruling): In key decisions leading up to March 2026, the Delhi High Court permitted domestic pharmaceutical leaders to manufacture and export generic Semaglutide to non-patent jurisdictions prior to the domestic patent expiration. This established that domestic patent rights cannot be leveraged to block global supply chains targeting unprotected territories. * Instant Market Demarcation: The expiration unlocked immediate domestic commercial launches. Leading pharma players - including Sun Pharma (marketing Noveltreat for weight management and Sematrinity for Type-2 diabetes), Dr. Reddy's (Obeda), and Zydus - introduced DCGI-approved options at price reductions of 50% to 70% compared to original innovator pricing. * Global Hub Capabilities: By establishing early production frameworks and bioequivalent pen-injector manufacturing systems, Indian generic manufacturers solidified their position as the primary global manufacturing hub for GLP-1 therapies targeting emerging markets. Strategic action plan for life sciences enterprises. To navigate the post-patent GLP-1 market and safeguard cross-border commercial opportunities, pharmaceutical brand managers should take the following steps: * Perform Multi-Jurisdictional FTO Audits: Map local patent portfolios carefully. While India's patent expired in March 2026, corresponding patents in major Western markets (such as the US and EU) remain active into 2031-2032. Ensure strict geographical isolation of export supply chains. * Audit Device and Delivery IP: Patent protection often extends beyond the active pharmaceutical ingredient to auto-injector pens and delivery mechanisms. Ensure generic delivery devices maintain clear non-infringing designs. * Establish Regulatory Compliance Trails: Maintain robust documentation confirming bioequivalence and DCGI approvals to mitigate post-launch regulatory or quality challenges from competitors. * Leverage Non-Patent Market Windows: Deploy export-oriented manufacturing strategies to capture first-mover advantage in markets across South Asia, Africa, and Latin America where patent coverage has lapsed or was never granted. #ExyIP #ExyIntellectualProperty #IPUpdate #IntellectualProperty #TrademarkLaw #IPknowledge

Associated Press

Aug 19th, 2026

Dr. Reddy's Laboratories faces securities fraud probe after $28M semaglutide provision tanks stock 9.4%

The Law Offices of Frank R. Cruz has announced an investigation into Dr. Reddy's Laboratories concerning possible violations of federal securities laws. The investigation follows Dr. Reddy's first quarter fiscal 2027 earnings announcement on 22 July 2026. The company reported earnings per share of only $0.06, impacted by a ₹2.4 billion provision related to out-of-specification semaglutide batches. CEO Erez Israeli stated the quarter's EBITDA margin was adversely affected by semaglutide-related challenges, including lower sales, provision for rejected batches, loss of production-linked incentives and other associated costs. Following the announcement, Dr. Reddy's stock price fell $1.18, or 9.4%, closing at $11.38 on 22 July 2026.

Dr. Reddy's Laboratories

Professional Sales Representative

About the job